Expert Rev Endocrinol Metab. 2010;5(4):507-516. The 'Summary of Product Characteristics' for BIAsp 30 has recently been changed to reflect data from the clinical trial program. These data showed that ...

Merilog, a biosimilar to Novolog, offers a more affordable insulin option for type 2 diabetes patients, enhancing treatment accessibility. The GEMELLI-1 trial confirmed Merilog's noninferiority to the ...

HAMBURG, Germany -- Faster-acting insulin aspart was safe for pregnant women with type 1 or 2 diabetes and resulted in fewer events of hypoglycemia, the randomized CopenFast trial found. The mean ...

More than three years after approving two biosimilars referencing Sanofi’s long-acting insulin Lantus, the FDA has signed off on a rapid-acting insulin biosimilar for the first time. The agency has ...

The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and children with diabetes, the agency announced Friday. Like its reference ...

COPENHAGEN, Jan 8 (Reuters) - Denmark's Novo Nordisk (NOVOb.CO), opens new tab said on Monday its COMBINE 3 phase 3a drug trial had shown that a weekly injection of IcoSema was superior in controlling ...

Sanofi will cut insulin prices by 70% or more and cap out-of-pocket costs at $35 for people with commercial insurance Sanofi follows Eli Lilly and Novo Nordisk in announcing insulin price cuts.

COMBINE 3 phase 3a trial successfully completed with once-weekly IcoSema demonstrating non-inferior reduction in HbA1c versus daily basal-bolus treatment (insulin glargine U100 and insulin aspart) in ...

Treatment with once-weekly IcoSema demonstrated noninferiority in HbA1c reduction at week 52 compared with insulin glargine and aspart. Treatment with once-weekly IcoSema, a fixed-ratio combination of ...

After slashing the U.S. prices of several of its insulin products by 75% at the start of 2024, Novo Nordisk is ending the year by announcing similar price reductions for most of its other insulins for ...